Both biotechs are a bit risky, but could benefit from clinical progress this year -- and the upside would be huge. CRISPR has ...

The vaccines subsector received a big fillip from Covid, but its potential extends far beyond combating pandemics. Dr Mike ...

Although the year brought a steady stream of new treatments, tests, and cutting-edge science, experts worry about how ...

A study led by researchers at Moffitt Cancer Center found that normal cells surrounding a tumor, known as cancer-associated ...

From new imaging and targeted therapies to patient journeys, 2025 highlighted key advances and personal stories in lung ...

A new study suggests that the immune checkpoint inhibitor, durvalumab, may offer new treatment options for patients living ...

Zoldonrasib targets KRAS G12D-mutated non-small cell lung cancer, receiving FDA breakthrough therapy designation for its ...

Multiple big pharma companies are reported to be circling Revolution, a cancer biotech with a market cap of $23bn.

KAIST researchers have developed a way to reprogram immune cells already inside tumors into cancer-killing machines. A drug ...

Researchers are targeting dormant tumour cells that might explain why some cancers reappear long after successful treatment.

The therapy is a highly advanced form of radiation therapy that uses charged particles in the form of a proton that that gets ...

The new Phase III study will test calderasib in a chemo-free regimen for G12C-mutated patients regardless of PD-L1 status.